Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned for substantial growth within the oncology market, with its product candidates NVL-520 and NVL-655 demonstrating deep and durable antitumor responses, which could redefine treatment paradigms and target an estimated peak revenue opportunity of over $3.6 billion in the oncogene-driven non-small cell lung cancer (NSCLC) market. As the market evolves, Nuvalent's offerings could capture market share from established therapies like Alecensa, which is projected to generate around $1.7 billion in 2025, highlighting the potential for increased revenue with improved precision in treatment options. Additionally, the anticipated positive outcomes from ongoing clinical trials, such as the ALKAZAR study, indicate a promising future for Nuvalent’s product pipeline, bolstering investor confidence in the company's growth trajectory and market penetration.

Bears say

Nuvalent Inc faces several challenges that contribute to a negative outlook on its stock. Key concerns include the potential for compromised regulatory approval due to safety signals and the possibility of delays in commercialization stemming from negative trial outcomes or slower trial enrollment. Additionally, the competitive landscape for ALK and ROS1 NSCLC therapies presents significant risks, compounded by the company's need for adequate capital to support its research efforts.

Nuvalent (NUVL) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 14 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.